LMV-12 / Nanchang Helioeast Pharma - LARVOL DELTA

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Hunan Province Tumor Hospital | Phase classification: P ➔ P1/2 | N=20 ➔ 120 | Trial completion date: Jul 2025 ➔ Jul 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment change • Metastases • Phase classification • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET • RET

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Hunan Province Tumor Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET • RET

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Hunan Province Tumor Hospital | Trial completion date: Nov 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET • RET